280 related articles for article (PubMed ID: 35489743)
21. Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up.
Ishihara H; Yuki N; Ishiyama R; Ikeda T; Kobari Y; Fukuda H; Yoshida K; Shimmura H; Hashimoto Y; Iizuka J; Kondo T; Takagi T
Jpn J Clin Oncol; 2024 May; 54(5):577-583. PubMed ID: 38251783
[TBL] [Abstract][Full Text] [Related]
22. Editorial Comment on "Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma".
Teishima J
Int J Urol; 2023 Sep; 30(9):752-753. PubMed ID: 37218357
[No Abstract] [Full Text] [Related]
23. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Emamekhoo H; Olsen MR; Carthon BC; Drakaki A; Percent IJ; Molina AM; Cho DC; Bendell JC; Gordan LN; Rezazadeh Kalebasty A; George DJ; Hutson TE; Arrowsmith ER; Zhang J; Zoco J; Johansen JL; Leung DK; Tykodi SS
Cancer; 2022 Mar; 128(5):966-974. PubMed ID: 34784056
[TBL] [Abstract][Full Text] [Related]
26. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
27. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive Nephrectomy After Combination of Nivolumab Plus Ipilimumab for Mucinous Tubular and Spindle Cell Carcinoma of the Kidney With Bone Metastases: A Case Report.
Furubayashi N; Taguchi K; Negishi T; Miura A; Sato Y; Miyoshi M; Nakamura M
In Vivo; 2022; 36(1):510-521. PubMed ID: 34972756
[TBL] [Abstract][Full Text] [Related]
29. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Regan MM; Jegede OA; Mantia CM; Powles T; Werner L; Motzer RJ; Tannir NM; Lee CH; Tomita Y; Voss MH; Plimack ER; Choueiri TK; Rini BI; Hammers HJ; Escudier B; Albiges L; Huo S; Del Tejo V; Stwalley B; Atkins MB; McDermott DF
Clin Cancer Res; 2021 Dec; 27(24):6687-6695. PubMed ID: 34759043
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A
J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
[TBL] [Abstract][Full Text] [Related]
33. Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Atkins MB; Jegede OA; Haas NB; Mcdermott DF; Bilen MA; Stein M; Sosman J; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Einstein D; Catalano PJ; Hammers H; Regan MM
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604810
[TBL] [Abstract][Full Text] [Related]
34. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study).
Kojima T; Kato R; Sazuka T; Yamamoto H; Fukuda S; Yamana K; Nakaigawa N; Sugino Y; Hamamoto S; Ito H; Murakami H; Obara W
Jpn J Clin Oncol; 2022 Nov; 52(11):1345-1352. PubMed ID: 35920793
[TBL] [Abstract][Full Text] [Related]
35. Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study.
Ishihara H; Takagi T; Yoshida K; Hashimoto Y; Kondo T; Tanabe K
Int J Urol; 2021 Oct; 28(10):1075-1076. PubMed ID: 34218475
[No Abstract] [Full Text] [Related]
36. First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.
Wan X; Zhang Y; Tan C; Zeng X; Peng L
JAMA Oncol; 2019 Apr; 5(4):491-496. PubMed ID: 30789633
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of immunotherapy-based immediate cytoreductive nephrectomy vs. deferred cytoreductive nephrectomy in metastatic renal cell carcinoma.
Shen XP; Xie M; Wang JS; Guo X
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5684-5691. PubMed ID: 37401306
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
39. Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.
Yang Y; Mori SV; Li M; Hinkley M; Parikh AB; Collier KA; Miah A; Yin M
Cancer Med; 2022 Apr; 11(7):1669-1677. PubMed ID: 35138046
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]